Psychedelic therapy uses substances like psilocybin, MDMA, and ibogaine in controlled, supervised settings to treat conditions such as depression, PTSD, anxiety, and addiction by enabling psychological insight and emotional breakthroughs. These drugs act mainly as 5-HT2A (serotonin) receptor agonists, promoting changes in perception and mood and encouraging cortical neuroplasticity. Growing clinical evidence suggests durable benefits, prompting expanded research and interest in regulated treatment pathways. Proposals to broaden access, such as initiatives supporting ibogaine for opioid addiction, aim to help patients unresponsive to existing therapies but require strict safety protocols, standardized dosing, and careful monitoring to manage cardiac and neuropsychiatric risks.